Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma

被引:5
|
作者
Yabuno, Akira [1 ]
Matsushita, Hirokazu [2 ]
Hamano, Tetsutaro [1 ]
Tan, Tuan Zea [3 ]
Shintani, Daisuke [1 ]
Fujieda, Nao [2 ]
Tan, David S. P. [3 ,4 ,5 ]
Huang, Ruby Yun-Ju [6 ]
Fujiwara, Keiichi [1 ]
Kakimi, Kazuhiro [2 ]
Hasegawa, Kosei [1 ]
机构
[1] Saitama Med Univ, Int Med Ctr, Dept Gynecol Oncol, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan
[2] Univ Tokyo Hosp, Dept Immunotherapeut, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan
[3] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore
[4] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore
[5] Natl Univ Singapore Hosp, Natl Univ Canc Inst, Singapore, Singapore
[6] Natl Taiwan Univ, Sch Med, Coll Med, Taipei, Taiwan
关键词
DISTINCT-HISTOLOGIC-TYPE; POOR-PROGNOSIS; T-CELLS; CANCER; CHEMOTHERAPY; RESISTANCE; SURVIVAL;
D O I
10.1038/s41598-020-75536-1
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Serum cytokine and chemokine networks may reflect the complex systemic immunological interactions in cancer patients. Studying groups of cytokines and their networks may help to understand their clinical biology. A total of 178 cases of ovarian cancer were analyzed in this study, including 73 high-grade serous (HGSC), 66 clear cell (CCC) and 39 endometrioid carcinomas. Suspension cytokine arrays were performed with the patients' sera taken before the primary surgery. Associations between each cytokine and clinicopathological factors were analyzed in all patients using multivariate linear regression models, and cluster analyses were performed for each histotype. In the multivariate analyses, twelve of 27 cytokines were correlated with histotypes. Cluster analyses in each histotype revealed 2 cytokine signatures S1 and S2 in HGSC, and similarly C1 and C2 in CCC. Twenty-two of 27 cytokines were commonly clustered in HGSC and CCC. Signature S1 and C1 included IL-2,6,8,15, chemokines and angiogenic factors, whereas signature S2 and C2 included IL-4,5,9,10,13, TNF-alpha and G-CSF. Four subgroups based on a high or low level for each signature were identified, and this cluster-based classification demonstrated significantly different progression-free and overall survivals for CCC patients (P=0.00097 and P=0.017).
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma
    Al-Barrak, J.
    Santos, J. L.
    Tinker, A.
    Hoskins, P.
    Gilks, C. B.
    Lau, H.
    Swenerton, K. D.
    GYNECOLOGIC ONCOLOGY, 2011, 122 (01) : 107 - 110
  • [2] Proposing a molecular classification associated with hypercoagulation in ovarian clear cell carcinoma
    Tamura, Ryo
    Yoshihara, Kosuke
    Matsuo, Koji
    Yachida, Nozomi
    Miyoshi, Ai
    Takahashi, Kotaro
    Sugino, Kentaro
    Yamaguchi, Manako
    Mori, Yutaro
    Suda, Kazuaki
    Ishiguro, Tatsuya
    Okuda, Shujiro
    Motoyama, Teiichi
    Nakaoka, Hirofumi
    Kikuchi, Akira
    Ueda, Yutaka
    Inoue, Ituro
    Enomoto, Takayuki
    GYNECOLOGIC ONCOLOGY, 2021, 163 (02) : 327 - 333
  • [3] Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival
    Diaz, Elena S.
    Walts, Ann E.
    Karlan, Beth Y.
    Walsh, Christine S.
    GYNECOLOGIC ONCOLOGY, 2013, 131 (03) : 541 - 545
  • [4] Poor prognosis associated with venous thromboembolism in Asian patients with ovarian clear cell carcinoma
    Tse, Ka Yu
    Ip, Philip Pun Ching
    Lau, Suk Kwan
    Ng, Tong Now
    Tam, Kar Fai
    Cheung, Annie Nga Yin
    Ngan, Hextan Yuen Sheung
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (06) : 903 - 910
  • [5] Patterns of recurrence and impact on survival in patients with clear cell ovarian carcinoma
    Hogen, Liat
    Vicus, Danielle
    Ferguson, Sarah Elizabeth
    Gien, Lilian T.
    Nofech-Mozes, Sharon
    Lennox, Genevieve K.
    Bernardini, Marcus Q.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (07) : 1164 - 1169
  • [6] Expression of angiogenic chemokines in ovarian clear cell carcinoma
    Quattrocchi, Livia
    Sisson, Melanie
    Green, Andrew
    Martin, Stewart G.
    Durrant, Lindy
    Deen, Suha
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2013, 39 (01) : 297 - 304
  • [7] Clinical characteristics with patterns of relapse and survival analysis of ovarian clear cell carcinoma
    Kaur, S.
    Kerkar, R. A.
    Maheshwari, A.
    Shylasree, T. S.
    Gupta, S.
    Deodhar, K.
    INDIAN JOURNAL OF CANCER, 2016, 53 (02) : 288 - 291
  • [8] Identification of Intranuclear Inclusions is Useful for the Cytological Diagnosis of Ovarian Clear Cell Carcinoma
    Naka, Masaki
    Ohishi, Yoshihiro
    Kaku, Tsunehisa
    Watanabe, Sumiko
    Tamiya, Sadafumi
    Ookubo, Fumihiko
    Kato, Kiyoko
    Oda, Yoshinao
    Sugishima, Setsuo
    DIAGNOSTIC CYTOPATHOLOGY, 2015, 43 (11) : 879 - 884
  • [9] Identification of LEFTY as a molecular marker for ovarian clear cell carcinoma
    Akiya, Masashi
    Yamazaki, Masaaki
    Matsumoto, Toshihide
    Kawashima, Yusuke
    Oguri, Yasuko
    Kajita, Sabine
    Kijima, Daiki
    Chiba, Risako
    Yokoi, Ako
    Takahashi, Hiroyuki
    Kodera, Yoshio
    Saegusa, Makoto
    ONCOTARGET, 2017, 8 (38) : 63646 - 63664
  • [10] Cytokine gene expression signature in ovarian clear cell carcinoma
    Yanaihara, Nozomu
    Anglesio, Michael S.
    Ochiai, Kazunori
    Hirata, Yukihiro
    Saito, Misato
    Nagata, Chie
    Iida, Yasushi
    Takakura, Satoshi
    Yamada, Kyosuke
    Tanaka, Tadao
    Okamoto, Aikou
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2012, 41 (03) : 1094 - 1100